|
9th Annual Conference Of The British HIV Association [BHIVA]24 – 26 April 2003, University of Manchester
|
[AUTHOR(S):] HA Leake Date1, CA Sabin2 , D Churchill1, G Dean1, D Williams1 and M Fisher1
1 Brighton and Sussex University Hospitals, Brighton, and 2 Royal Free and University College Medical School, London, UK
BHIVA Conf 2003 Apr 24-26;9:O10
INTRODUCTION: A weekly multidisciplinary viral load meeting (VLm) identifies patients eligible for highly active antiretroviral therapy (HAART) and those on therapy with VL >50 copies/ml. Treatment decisions are aided by appropriate use and expert interpretation of resistance and drug-level assays. Concordance and adherence are promoted by multidisciplinary involvement before HAART initiation and ongoing support thereafter.
METHODS: Observational cohort study of patients at an HIV centre on HAART (on-treatment analysis from weekly VLm), including those starting first HAART in 1999–2002 [intent to treat (ITT)].
RESULTS: On-treatment analysis (all patients on HAART >6 months):
| Year | Total no. clinic | % not on | % on HAART | |
| attenders (no. on | HAART at VLm, | >6 months + VL <50, | ||
| HAART) on 31/12 | median (range) | median (range) | ||
| 2001 | 818 (494) | 28 (16–48) | 89 (80–100) | |
| 2002 | 895 (606) | 25 (10–36) | 92 (75–97) |
An ITT analysis of antiretroviral-naïve patients starting HAART at this centre from 1 August 1999 with over 6 months' follow-up will be presented, including data on clinical trial participation, treatment outcomes and reasons for stopping/switching.
DISCUSSION: VL suppression rates (<50 copies/ml) of >90% can be achieved in routine clinical practice by the adoption of a structured multidisciplinary approach.
PRESENTING AUTHOR: HA Leake Date
030424
O10
Copyright © 2003 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD